Skip to main content
Role of the Incretin Pathway in the Pathogenesis of Type 2 Diabetes Mellitus
Cleveland Clinic Journal of Medicine
  • Jeffrey S. Freeman, Philadelphia College of Osteopathic Medicine
Document Type
Publication Date
Nutrient intake stimulates the secretion of the gastrointestinal incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which exert glucose-dependent insulinotropic effects and assist pancreatic insulin and glucagon in maintaining glucose homeostasis. GLP-1 also suppresses glucose-dependent glucagon secretion, slows gastric emptying, increases satiety, and reduces food intake. An impaired incretin system, characterized by decreased responsiveness to GIP and markedly reduced GLP-1 concentration, occurs in individuals with type 2 diabetes mellitus (T2DM). The administration of GLP-1 improves glycemic control, but GLP-1 is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4). Exenatide, a DPP-4-resistant exendin-4 GLP-1 receptor agonist, exhibits the glucoregulatory actions of GLP-1 and reduces body weight in patients with T2DM. It may possess cardiometabolic actions with the potential to improve the cardiovascular risk profile of patients with T2DM. DPP-4 inhibitors such as sitagliptin and saxagliptin increase endogenous GLP-1 concentration and demonstrate incretin-associated glucoregulatory actions in patients with T2DM. DPP-4 inhibitors are weight neutral. A growing understanding of the roles of incretin hormones in T2DM may further clarify the application of incretin-based treatment strategies.
PubMed ID

This article was published in Cleveland Clinic Journal of Medicine, Volume 76, Supplement 5, December 2009, Pages S12-S19.

The published version is available at

Copyright © 2009 The Cleveland Clinic Foundation

Citation Information
Jeffrey S. Freeman. "Role of the Incretin Pathway in the Pathogenesis of Type 2 Diabetes Mellitus" Cleveland Clinic Journal of Medicine Vol. 76 Iss. Supplement 5 (2009) p. S12 - S19
Available at: